瑞康医药上市14周年：利润下滑75%，市值较峰值蒸发85%

Core Viewpoint - Ruikang Pharmaceutical has experienced significant growth since its listing in June 2011, with a market value increase from 2.29 billion to 4.59 billion yuan, but recent years have shown a notable decline in both revenue and profit [1][3]. Revenue Analysis - In 2020, Ruikang Pharmaceutical achieved revenue of 27.20 billion yuan, which decreased to 7.97 billion yuan in 2024, representing a cumulative decline of over 70% in the past five years [4]. Profit Analysis - The company's net profit attributable to shareholders was 261 million yuan in 2020, dropping to 21 million yuan in 2024, indicating a continuous decline in profitability [5]. Business Diversification - Ruikang Pharmaceutical's main business segments include pharmaceutical distribution, vaccine and medical device logistics, third-party logistics, medical information services, and more, with pharmaceuticals accounting for 75.16% of revenue and medical devices 22.59% [3]. Market Value Fluctuation - Since its peak market value of 30.81 billion yuan on May 20, 2015, the company's market value has decreased by 26.22 billion yuan, resulting in an 85.10% reduction from its peak [7].